BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease are still observed within a short time after trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Translational Medicine
Subjects:
Relapsed/Refractory multiple myeloma (R/R MM)
BCMA CAR T-cell therapy
Pomalidomide
Combination therapy
Online Access:https://doi.org/10.1186/s12967-024-05772-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-024-05772-w

Similar Items